# Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

> **NCT07084311** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **n-Lorem Foundation** · enrollment: 1 (actual)

## Conditions studied

- Dentatorubral-Pallidoluysian Atrophy

## Interventions

- **DRUG:** nL-ATN1-002

## Key facts

- **NCT ID:** NCT07084311
- **Lead sponsor:** n-Lorem Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07084311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07084311, "Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07084311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*